hapabapa
Nuvation Bio (NYSE:NUVB) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its oral antitumor agent Ibtrozi as a treatment for certain patients with non-small cell lung cancer.
Specifically, the FDA has approved the tyrosine kinase inhibitor
